Modafinil from 1970 till today
Provigil, Modavigil, Modiodal, Modalert, Modvigil…?
Modafinil (chemically named as 2-[(diphenylmethyl)sulfinyl]acetamide) is a drug developed by neurophysiology medicine professor Michel Jouvet and Lafon Laboratories in France. although most typically known as Modafinil,it’s sold-out worldwide below numerous brand names such as Provigil (sold in GB, Croatia, Poland, Hong Kong, Italy, south Korea, Thailand, UAE), Modavigil (sold in Australia), Modiodal (sold in France, Japan, Singapore), Modalert, Modapro, Modvigil (all 3 sold-out in India), Modasomil (sold in Switzerland), and SpierX (sold in Malaysia).
It is a strong stimulant that not only improves memory, intellectual keenness, and alternative mental activities, however is incredibly efficient at restoring your brains cognitive functions throughout times of reduced wakefulness.
The drug works by inducing your body to extend the production of monoamines that are specific neurotransmitters. These neurotransmitters stimulate the hypothalamus that is responsible for manufacturing hormones that control sleep and also the circadian rhythm, among many alternative things.
Developed to treat symptoms of narcolepsy (episodes of uncontrollable sleep), it helps restore alertness and fight tiredness and fatigue.
Modafinil was originally synthesized within the 1970’s in France. After studies were completed in 1986, it had been determined that not only was this drug effective for treating narcolepsy, it also temporarily reduced the necessity to sleep in healthy patients.
In 1993, Lafon Laboratories hired the rights to Modafinil to a company within the United States known as Cephalon. After five years, it had been officially Food and Drug Administration approved and sold-out under the name Provigil as a remedy against narcolepsy and obstructive sleep disorder.
In 2007, the Food and Drug Administration approved Armodafinil, hitherto sold as Nuvigil. Armodafinil is technically considered a chemical compound of Modafinil. Armodafinil only consists of the (R)-enantiomer, which is the active element of Modafinil. This new formula was marketed to offset the financial losses caused by a market soon to be flooded with low-cost generic drugs, as Cephalon was expecting to lose the exclusive promoting rights for Modafinil. Armodafinil was to be used as a treatment for narcolepsy, shift work sleep disorder, and obstructive sleep disorder.
In 2010, the bureau turned down asking by Cephalon to promote Nuvigil because the 1st pharmaceutical treatment for jet lag.
Modafinil’s primary indication is for the treatment of narcolepsy, but it’s usually prescribed for those with attention deficit disorder, treatment-resistant depression, alternative antidepressant drug therapies, and multiple sclerosis (MS). Exploratory studies also are turning up promising results for the drug’s attainable advantages in remedying depressive symptoms.
Narcolepsy could be a neurological disorder that causes uncontrollable daytime sleepiness that’s caused by then absence of orexin peptides within the brain that are responsible for dominant wakefulness and sleep-suppression. Modafinil targets these orexin neurons and activates them that successively promotes wakefulness.
Other common illnesses and diseases it’s used to treat include fibromyalgia, chronic fatigue syndrome, myotonic dystrophy, multiple sclerosis (MS), cerebral palsy, and Parkinson’s disease.